Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Schmidt

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Advances in Chronic Kidney Disease|January 18, 2006
Outcomes study of a customer relations educational program in dialysis practiceJill Schmidt
American Journal of Clinical Oncology|August 8, 2006
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinomaVictoria J Sinibaldi, Kathy Elza-Brown, Jill Schmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancerMichael A Carducci, Luna Musib, Merrill S Kies, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Advances in Chronic Kidney Disease|January 18, 2006
Outcomes study of a customer relations educational program in dialysis practiceJill Schmidt
American Journal of Clinical Oncology|August 8, 2006
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinomaVictoria J Sinibaldi, Kathy Elza-Brown, Jill Schmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancerMichael A Carducci, Luna Musib, Merrill S Kies, et al.
Pageof 1